CLINICAL_TRIALS ClinicalTrials.gov record update

The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03758781
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:12.979728+00:00
Published At: 2023-04-14T00:00:00+00:00
Record Updated At: 2023-04-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Cancer", "Recurrent Cancer", "Solid Tumor", "Renal Cell Carcinoma", "Urothelial Carcinoma", "NSCLC", "Squamous Cell Carcinoma", "Non-Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-04-14"
protocolSection.identificationModule.nctId: "NCT03758781"
protocolSection.identificationModule.officialTitle: "The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.